Synergie Medication Collective
Synergie Medication Collective is a transparent, pass-through medication contracting organization founded in 2023 by Blue Cross and Blue Shield-affiliated health plans to negotiate medical benefit drug rebates and value-based cell and gene therapy contracts across 80M+ member lives.
- Company typePrivate
- Founded2023
- HeadquartersClearwater, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Synergie Medication Collective does
Synergie Medication Collective is an independent medication contracting organization founded in 2023 by a group of Blue Cross and Blue Shield-affiliated companies — including BCBS of Massachusetts, BCBS of Michigan, Blue Shield of California, Highmark, and Independence Blue Cross — with financial backing from BCBSA, Elevance Health, Evio Pharmacy Solutions, and Prime Therapeutics (including Magellan Rx Management). Headquartered in Clearwater, Florida, the company focuses exclusively on contracting for medical benefit drugs (infusible, injectable, and gene therapies administered in clinical settings) rather than pharmacy benefit medications, addressing the portion of specialty spend that traditional PBM-led contracting models typically under-serve.
The company operates two product lines under the SelectMed+ suite. SelectMed+ Rebates runs an annual manufacturer bidding process that negotiates pricing on more than 100 preferred medical benefit drugs, compiled in the publicly downloadable SelectMed+ Medical Drug List, covering 80M+ member lives with 70%+ compliance rates among participating health plans. Cell & Gene+ delivers integrated cell and gene therapy solutions including Gene+ RiskProtection (financial risk pooling for multi-million-dollar therapies), Gene+Outcomes (value-based contracts that tie manufacturer payments to clinical outcomes), and Cell & Gene+ Patient Navigation (assistance identifying top treatment centers).
The business model is a fully transparent, pass-through structure: 100% of negotiated rebates are returned to participating health plans, and Synergie monetizes through administrative fees or contractual arrangements at the plan-contract level. Distribution is exclusively through participating Blues and independent health plans (twelve independent plans are named in addition to the founding Blues), giving the company collective reach across nearly 100 million Americans and providing substantial manufacturer negotiating leverage without direct-to-employer or direct-to-consumer sales motion.
Synergie Medication Collective firmographics
Firmographics- Name
- Synergie Medication Collective
- Legal name
- Synergie Medication Collective, LLC
- Website
- https://synergiecollective.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Synergie Medication Collective is a transparent, pass-through medication contracting organization founded in 2023 by Blue Cross and Blue Shield-affiliated health plans to negotiate medical benefit drug rebates and value-based cell and gene therapy contracts across 80M+ member lives.
- Ownership category
- akta.pro rank
Where Synergie Medication Collective is headquartered
LocationHeadquarters
- HQ city
- Clearwater
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Synergie Medication Collective business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Medical Rebate Contracting: Synergie negotiates rebates with pharmaceutical manufacturers on more than 100 preferred medical benefit medications. Rebates are secured through an annual bidding process and passed through 100% to participating health plans. Synergie acts as a fully transparent pass-through organization, generating revenue from administrative fees or contractual arrangements with health plan participants.
- Cell & Gene Therapy Solutions: Synergie offers integrated solutions for cell and gene therapies including risk protection, patient navigation, and outcomes-based contracting. These solutions are anchored by large data and risk pools and are made available through participating health plans.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Synergie Medication Collective product offering
Product offeringCore offering
Synergie Medication Collective is a medication contracting organization that negotiates rebates on more than 100 preferred medical-benefit drugs with pharmaceutical manufacturers on behalf of participating Blue Cross Blue Shield-affiliated and independent health plans, passing through 100% of rebates to those plans. It also provides Cell & Gene+ solutions — including financial risk protection, patient navigation to top U.S. treatment centers, and value-based contracts requiring manufacturers to refund or add value when gene therapies do not achieve defined clinical outcomes — covering nearly 100 million Americans.
Product overview
Synergie Medication Collective operates as a medication contracting organization offering a unified SelectMed+ product suite. The portfolio comprises two main product lines: SelectMed+ Rebates for medical drug rebate contracting covering 100+ products across 80M+ lives with 70%+ compliance rates, and Cell & Gene+ providing integrated solutions for high-cost cell and gene therapies (up to $3.5 million per therapy). Under Cell & Gene+, three sub-products address specific needs: Gene+ RiskProtection for financial volatility management, Cell & Gene+ Patient Navigation for treatment access support, and Gene+Outcomes for value-based contracting with outcome guarantees.
Differentiator
Problem solved
Functional benefit
Brands
- SelectMed+: Product suite offering medical drug rebates and cell & gene therapy solutions
- SelectMed+ Rebates
- Cell & Gene+
- Gene+ RiskProtection
- Gene+ Outcomes
- Cell & Gene+ Patient Navigation
Products and services
- SelectMed+ Rebates A medical-benefit drug rebate program through which Synergie negotiates with pharmaceutical manufacturers on behalf of participating Blue Cross Blue Shield-affiliated and independent health plans, covering 100+ preferred medications reflected in the SelectMed+ Medical Drug List, with 70%+ compliance rates and 80M+ lives covered. Designed for U.S. health plan sponsors seeking transparent, pass-through rebate contracting for high-cost medical-benefit drugs.
- Cell & Gene+ An integrated solutions portfolio for high-cost cell and gene therapies, providing financial risk protection, patient navigation to top U.S. treatment centers, and outcomes-based/value-based contracting with pharmaceutical manufacturers. Built on large data and risk pools and made available to participating health plans serving nearly 100 million Americans.
- Gene+ RiskProtection A financial protection product that uses large, pooled risk arrangements to alleviate the financial volatility and burden on plan sponsors associated with multi-million-dollar upfront payments for gene therapies, delivering competitive rates and industry-leading protection through the Cell & Gene+ suite.
- Cell & Gene+ Patient Navigation A patient support service within the Cell & Gene+ suite that assists patients and health plan members in identifying and accessing top-quality cell and gene therapy treatment centers across the United States, helping ensure access to these therapies at affordable prices through participating health plans.
- Gene+ Outcomes Value-based contracts (also known as outcomes-based contracts) within the Cell & Gene+ suite that require pharmaceutical manufacturers of gene therapies to provide refunds or additional value to participating health plans if the drug does not achieve defined clinical outcomes over a defined time period, aligning price with clinical value.
Quantifiable outcome
- 80M+ lives covered with industry-leading participation in the SelectMed+ Rebate program
- +3 more outcomes
Companies that use Synergie Medication Collective
Customer profileNamed customers17 records
Segments3 records
Ideal customer profiles1 record
Synergie Medication Collective technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Synergie Medication Collective partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Prime Therapeutics (Including Magellan Rx Management)corePrime Therapeutics, including Magellan Rx Management as part of Prime, is an investor in Synergie Medication Collective. Magellan Rx Management contributed market data referenced by Synergie, including projections on cell and gene therapy cost growth.
- Top Domain Experts (Unnamed)minorSynergie has partnered with top domain experts to ensure its solutions are best-in-class, particularly in the cell and gene therapy management space. Specific partner names are not disclosed.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Synergie Medication Collective competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat6 records
Customer concentration
Synergie Medication Collective social profiles
Digital presenceSynergie Medication Collective financial estimates
Financial estimateRevenue estimate
Valuation estimate
Synergie Medication Collective leadership team
Management profileNumber of profiles
Profiles2 records
Synergie Medication Collective funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Synergie Medication Collective M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Synergie Medication Collective
What does Synergie Medication Collective do?
Synergie Medication Collective is a medication contracting organization that negotiates rebates on more than 100 preferred medical-benefit drugs with pharmaceutical manufacturers on behalf of participating Blue Cross Blue Shield-affiliated and independent health plans, passing through 100% of rebates to those plans. It also provides Cell & Gene+ solutions — including financial risk protection, patient navigation to top U.S. treatment centers, and value-based contracts requiring manufacturers to refund or add value when gene therapies do not achieve defined clinical outcomes — covering nearly 100 million Americans.
Is Synergie Medication Collective a public or private company?
Synergie Medication Collective is a private company. It is classified as corporate owned and is currently operating.
When was Synergie Medication Collective founded?
Synergie Medication Collective was founded in 2023. It employs 1 to 10 people.
Where is Synergie Medication Collective based?
Synergie Medication Collective is headquartered in Clearwater, United States, in the North America region.
How does Synergie Medication Collective make money?
Two revenue lines are on record. Medical Rebate Contracting is the primary driver. The others are cell & Gene Therapy Solutions.
Does Synergie Medication Collective have an API?
No public API is recorded for Synergie Medication Collective.